6:30 AM-7:55 AM

Complimentary Continental Breakfast Provided

7:55 AM-9 :00 AM

Welcome and General Session 7: Exploiting Viruses for Cancer Therapy


Howard L. Kaufman, MD—Chair
Rutgers Cancer Institute of New Jersey


Graham P. Pawelec, PhD—Chair
Universitätsklinikum Tübingen


Mary L. (Nora) Disis, MD
University of Washington



Stephen J. Russell, MD, PhD
Mayo Clinic

Viral Therapy


H. Kim Lyerly, MD
Duke University School of Medicine

Viral Vectors for Cancer Vaccines


John C. Bell, PhD
Ottawa Hospital Research Institute

Oncolytic Virus Vaccines


Panel Question and Answer

9:00 AM-9:45 AM

Keynote Lecture


Laurence Zitvogel, MD, PhD
Institut Gustave Roussy

Microbiome and Cancer Immunity

9:45 AM-10:15 AM Break
10:15 AM-11:30 AM

Oral Abstract Session C

James L. Gulley, MD, PhD - Co-Chair

National Cancer Institute at the National Institutes of Health

Ann W. Silk, MD - Co-Chair

Rutgers Cancer Institute of New Jersey


Abstract 111: Survival of neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor (KIR) genotypes and Fcγ-receptor polymorphisms.

First author: Holger Lode


Abstract 79: CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis.

First author: Limo Chen


Discussion: Graham P. Pawelec, PhD

Universitätsklinikum Tübingen


Abstract 80: Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.

First author: Howard Kaufman


Abstract 5: Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).

First author: Robert Ferris


Discussion: Ezra E.W. Cohen, MD

University of California, San Diego


Panel Question and Answer

11:45 AM-1:00 PM

Networking Roundtables: Where Does Immunotherapy Fit in Your Practice?


Expert faculty willl lead small-group discussions on lymphoma, lung cancer, ovarian cancer, gastric cancers, bladder cancer, myeloma, breast cancer, and pancreas and liver cancers.


For a list of the faculty participants, please visit Networking Opportunities.

11:30 AM-1:00 PM

Complimentary Boxed Lunch Provided

1:00 PM-2:15 PM

General Session 8: Resistance to Immunotherapy


James L. Gulley, MD, PhD—Chair
National Cancer Institute at the National Institutes of Health


Roger Lo, MD, PhD
University of California, Los Angeles

Melanoma Therapeutic Resistance: Interface between Mutation and Checkpoint Targeted Therapies


Katerina A. Politi, PhD
Yale School of Medicine

Rebiopsies in Lung Cancer with Resistance to Immunotherapy


Jennifer A. Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center

Mechanisms of Resistance to Immunotherapy in Melanoma


Panel Question and Answer

2:15 PM-2:45 PM Break
2:45 PM-4:00 PM

General Session 9: The Most Promising Therapeutic Combinations with Immune Checkpoints


Roy S. Herbst, MD, PhD—Chair
Yale University School of Medicine


Igor Puzanov, MD, MSCI, FACP
Roswell Park Cancer Institute

Combination Immunotherapy  with T-VEC


Robert L. Ferris, MD, PhD
University of Pittsburgh Cancer Institute

Checkpoint Targeting Beyond PD-1 to Overcome Therapeutic Escape: Is There Cross Talk?


Lawrence Fong, MD
University of California, San Francisco

How Do Immunotherapy Combinations All Work Together?


Roy S. Herbst, MD, PhD
Yale University School of Medicine

Promising Combinations in Lung Cancer with Immune Checkpoints


Panel Question and Answer